Literature DB >> 3819074

Pulmonary complications following methotrexate therapy.

T J Phillips, D H Jones, H Baker.   

Abstract

Methotrexate is frequently used in the treatment of severe psoriasis, and its hepatotoxicity has long been recognized by dermatologists. Pulmonary complications resulting from use of the drug are uncommon but should be considered in any patient on methotrexate who develops pulmonary symptoms in the absence of infection. We describe two patients, one who developed an acute pneumonitis and one with progressive pulmonary fibrosis following long-term, low-dose methotrexate for psoriasis. Early recognition of these complications by lung function testing and withdrawal of the drug, when necessary, may arrest or reverse methotrexate-induced lung disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3819074     DOI: 10.1016/s0190-9622(87)70052-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Systematic literature review investigating whether methotrexate causes chronic pulmonary fibrosis.

Authors:  Ed Quah; Constanta Amoasii; Tareg Mudawi; Julie Dawson
Journal:  Future Healthc J       Date:  2019-06

Review 2.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  The practical use of methotrexate in psoriasis.

Authors:  J P Tung; H I Maibach
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 4.  Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports.

Authors:  M R Hargreaves; A G Mowat; M K Benson
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 5.  Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature.

Authors:  Deepak M W Balak; Sascha Gerdes; Aurora Parodi; Laura Salgado-Boquete
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-11

6.  Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.

Authors:  Julie K Dawson; Edmond Quah; Ben Earnshaw; Constanta Amoasii; Tareg Mudawi; Lisa G Spencer
Journal:  Rheumatol Int       Date:  2021-01-29       Impact factor: 2.631

7.  Methotrexate and rheumatoid arthritis associated interstitial lung disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Jessica Lau; Leticia Kawano-Dourado; Jorge Rojas Serrano; Marco Sebastiani; Gouri Koduri; Eric Matteson; Karina Bonfiglioli; Marcio Sawamura; Ronaldo Kairalla; Lorenzo Cavagna; Emanuele Bozzalla Cassione; Andreina Manfredi; Mayra Mejia; Pedro Rodríguez-Henriquez; Montserrat I González-Pérez; Ramcés Falfán-Valencia; Ivette Buendia-Roldán; Gloria Pérez-Rubio; Esther Ebstein; Steven Gazal; Raphaël Borie; Sébastien Ottaviani; Caroline Kannengiesser; Benoît Wallaert; Yurdagul Uzunhan; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Lidwine Wemeau-Stervinou; René-Marc Flipo; Sylvain Marchand-Adam; Pascal Richette; Yannick Allanore; Claire Dromer; Marie-Elise Truchetet; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Kevin D Deane; Joshua J Solomon; Tracy Doyle; Jay H Ryu; Ivan Rosas; V Michael Holers; Catherine Boileau; Marie-Pierre Debray; Raphaël Porcher; David A Schwartz; Robert Vassallo; Bruno Crestani; Philippe Dieudé
Journal:  Eur Respir J       Date:  2021-02-11       Impact factor: 33.795

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.